EF
REGN icon

Empowered Funds’s Regeneron Pharmaceuticals REGN Stock Holding History

Empowered Funds’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-382
Closed -$276K – 671
2022
Q4 		$276K Buy
+382
New +$282K 0.02% 402

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Empowered Funds's REGN Position: Q1 2026 in Review

Empowered Funds reduced its Regeneron Pharmaceuticals (REGN) stake by 53% in Q1 2026, selling an estimated $13.4M and leaving 15,618 shares worth $12.1M. The position accounts for 0.08% of the portfolio, ranked #302.

Empowered Funds first reported a position in REGN in Q2 2020 and has held it in 17 quarters since. The position peaked at $25.5M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Empowered Funds held 15,618 shares of Regeneron Pharmaceuticals worth $12.1M as of Q1 2026.
  • Empowered Funds sold 17,442 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $13.4M.
  • Regeneron Pharmaceuticals made up 0.08% of Empowered Funds's portfolio in Q1 2026, its #302 holding.
  • Empowered Funds first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 17 quarters since.
  • Empowered Funds's Regeneron Pharmaceuticals position peaked at $25.5M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.